Results 251 to 260 of about 35,092 (349)

Allergic Rhinitis Amplifies Asthma Risk in Patients With Chronic Rhinosinusitis: A Large‐Scale Retrospective Cohort Analysis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are two highly prevalent airway diseases in the United States. While the coexistence of CRS and asthma is well recognized, less is known about the development of new‐onset asthma in CRS, particularly in the context of comorbid AR. This study assessed the impact of CRS and AR on
Austin J. Lee, Mohamad R. Chaaban
wiley   +1 more source

FACTOR ANALYSIS OF THE DETERIORATION OF WATER PIPELINES’ INNER SURFACES USING AN IN-PIPE ENDOSCOPE CAMERA

open access: diamond, 2019
Takaharu KUNIZANE   +6 more
openalex   +2 more sources

Biofilm Exoproteins From Staphylococcus Species Impede Re‐Epithelialization of Nasal Epithelial Cells During Wound Healing and Cease Ciliary Beat Frequency

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Introduction Chronic rhinosinusitis (CRS) is an inflammatory disease with many different contributing factors, including bacterial infection. CRS patients are typically managed with medical therapies; however, these treatments frequently fail, leaving surgery as the only viable option.
Sintayehu Ambachew   +8 more
wiley   +1 more source

Enhancing emergency endoscopy efficiency with an additional suction channel: In vitro assessment. [PDF]

open access: yesEndosc Int Open
Sasse A   +11 more
europepmc   +1 more source

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy